Loading...
Loading...
Drugmaker Shire's shares were down 4.5% early Friday, after the company announced poor results for a potential new treatment for one of its drugs. The Ireland-based company said a two-year phase 3 test of its MMX mesalamine drug to treat patients with a history of diverticulitis "did not meet the primary endpoint in reducing the rate of recurrence." Diverticulitis is a digestive disease in which pouches form, usually in the large intestine, and
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Trading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in